152 related articles for article (PubMed ID: 3476762)
1. [Serial changes in serum CA 19-9 levels in pancreatic cancer].
Saito K; Tajiri H; Yoshimori M; Hijikata A; Ohkura H; Nakamura K; Ozaki H
Gan No Rinsho; 1987 Aug; 33(9):1057-60. PubMed ID: 3476762
[TBL] [Abstract][Full Text] [Related]
2. Carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) in pancreatic cancer. Role of age and liver dysfunction.
Del Favero G; Fabris C; Panucci A; Basso D; Plebani M; Baccaglini U; Leandro G; Burlina A; Naccarato R
Bull Cancer; 1986; 73(3):251-5. PubMed ID: 3530354
[TBL] [Abstract][Full Text] [Related]
3. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
4. Multiparametric tumor marker (CA 19-9, CEA, AFP, POA) analyses of pancreatic juices and sera in pancreatic diseases.
Schmiegel WH; Eberl W; Kreiker C; Kalthoff H; Bützow GH; Jessen K; Klapdor R; Soehendra N; Wargenau M; Classen M
Hepatogastroenterology; 1985 Jun; 32(3):141-5. PubMed ID: 2410346
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases.
Satake K; Kanazawa G; Kho I; Chung Y; Umeyama K
Am J Gastroenterol; 1985 Aug; 80(8):630-6. PubMed ID: 2411125
[TBL] [Abstract][Full Text] [Related]
6. [Assay of serum elastase 1 in adenocarcinoma of the pancreas: diagnostic value, compared and combined study with serum CEA and CA 19-9].
Charneau J; Douay O; Daver A; Boyer J
Gastroenterol Clin Biol; 1988; 12(6-7):548-52. PubMed ID: 3166429
[TBL] [Abstract][Full Text] [Related]
7. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer.
Okusaka T; Okada S; Sato T; Wakasugi H; Saisho H; Furuse J; Ishikawa O; Matsuno S; Yokoyama S
Hepatogastroenterology; 1998; 45(21):867-72. PubMed ID: 9684148
[TBL] [Abstract][Full Text] [Related]
8. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer.
Nishida K; Tasaki N; Miyagawa H; Yoshikawa T; Kondo M
Am J Gastroenterol; 1988 Feb; 83(2):126-9. PubMed ID: 3422536
[TBL] [Abstract][Full Text] [Related]
9. Role of local and systemic factors in increasing serum glycoprotein markers of pancreatic cancer.
Fabris C; Basso D; Piccoli A; Meggiato T; Del Favero G; Fogar P; Panozzo MP; Faggian D; Vianello D; Plebani M
J Med; 1991; 22(3):145-56. PubMed ID: 1770322
[TBL] [Abstract][Full Text] [Related]
10. Serum CA 19-9 and CA 50 antigens in hemodialysis patients.
Docci D; Pistocchi E; Turci F; Baldrati L; Urbini S; Scaioli S
Clin Nephrol; 1987 Apr; 27(4):179-81. PubMed ID: 3472698
[TBL] [Abstract][Full Text] [Related]
11. [Clinical evaluation of a new tumor marker, CA 15-3, in breast cancer; a comparative study with CEA].
Komuro K; Watanabe K; Ishida T; Sakurai M; Amano R; Hagiwara H; Hara Y; Hanzawa T; Itsubo K
Gan To Kagaku Ryoho; 1986 Oct; 13(11):3145-9. PubMed ID: 3465273
[TBL] [Abstract][Full Text] [Related]
12. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
13. [Blood and urinary values of CEA and CA 19-9 in patients with bladder carcinoma].
Cicigoi A; Rocca Rossetti S; Piantino P; Cerchier A
Minerva Med; 1986 Nov; 77(42-43):1983-7. PubMed ID: 3464851
[TBL] [Abstract][Full Text] [Related]
14. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients.
Takasaki H; Uchida E; Tempero MA; Burnett DA; Metzgar RS; Pour PM
Cancer Res; 1988 Mar; 48(6):1435-8. PubMed ID: 3162196
[TBL] [Abstract][Full Text] [Related]
15. Serum markers and clinical data in diagnosing pancreatic cancer: a contrastive approach.
Fabris C; Del Favero G; Basso D; Piccoli A; Meggiato T; Angonese C; Plebani M; Leandro G; Burlina A; Naccarato R
Am J Gastroenterol; 1988 May; 83(5):549-53. PubMed ID: 3163228
[TBL] [Abstract][Full Text] [Related]
16. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
17. [Value of serum markers and clinical signs for the diagnosis of cancer of the pancreas].
Angonese C; Basso D; Del Favero G; Fabris C; Piccoli A; Infantino A; Naccarato R
Ann Med Interne (Paris); 1988; 139(2):127-8. PubMed ID: 3164986
[No Abstract] [Full Text] [Related]
18. [Tumor markers of pancreatic cancer].
Takami H; Hishinuma S; Shintoku J; Furuuchi T; Ogata Y; Abe O
Gan To Kagaku Ryoho; 1985 Feb; 12(2):212-9. PubMed ID: 3855615
[TBL] [Abstract][Full Text] [Related]
19. [Tumor markers in the diagnosis of tumors in the subhepatic area].
Dufek V; Petrtýl J; Klener P; Chmel J
Vnitr Lek; 1994 Jun; 40(6):350-3. PubMed ID: 8073643
[TBL] [Abstract][Full Text] [Related]
20. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]